• Aclaris Therapeutics posted a wider Q1 net loss of $19.8 million, or $0.15 per share, versus a $15.1 million loss a year earlier.
• Revenue rose 37.18% to $2 million, driven by higher royalties under Lilly and Sun Pharma license agreements.
• R&D expense climbed to $15.7 million from $11.6 million, while G&A costs increased to $6.7 million from $6.1 million.
• Cash, cash equivalents and marketable securities increased to $190.8 million as of March 31, supported by $59.8 million in gross proceeds from a March stock sale; cash runway expected to fund operations through end of 2028.
• Phase 1a SAD/MAD top-line results for ATI-052 showed an estimated half-life of about 45 days with sustained target inhibition, while top-line readouts from Phase 1b proof-of-concept trials in atopic dermatitis and asthma are expected in H2 2026 and a Phase 2 trial of bosakitug in atopic dermatitis is due in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070659PRIMZONEFULLFEED9714693) on May 07, 2026, and is solely responsible for the information contained therein.